369 related articles for article (PubMed ID: 26048361)
1. Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.
Chi OZ; Wu CC; Liu X; Rah KH; Jacinto E; Weiss HR
Neuromolecular Med; 2015 Sep; 17(3):305-13. PubMed ID: 26048361
[TBL] [Abstract][Full Text] [Related]
2. Increased cerebral oxygen consumption in Eker rats and effects of N-methyl-D-aspartate blockade: Implications for autism.
Weiss HR; Liu X; Zhang Q; Chi OZ
J Neurosci Res; 2007 Aug; 85(11):2512-7. PubMed ID: 17549750
[TBL] [Abstract][Full Text] [Related]
3. Cerebral O(2) consumption in young Eker rats, effects of GABA blockade: implications for autism.
Weiss HR; Liu X; Chi OZ
Int J Dev Neurosci; 2008 Aug; 26(5):517-21. PubMed ID: 18282678
[TBL] [Abstract][Full Text] [Related]
4. Reduced effect of stimulation of AMPA receptors on cerebral O₂ consumption in a rat model of autism.
Weiss HR; Liu X; Grewal P; Chi OZ
Neuropharmacology; 2012 Oct; 63(5):837-41. PubMed ID: 22722031
[TBL] [Abstract][Full Text] [Related]
5. Effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor blockade on increased cerebral O(2) consumption in Eker rats.
Weiss HR; Liu X; Hunter C; Chi OZ
Brain Res; 2009 Oct; 1294():138-43. PubMed ID: 19686708
[TBL] [Abstract][Full Text] [Related]
6. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
Kenerson H; Dundon TA; Yeung RS
Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
8. Effects of rapamycin on cerebral oxygen supply and consumption during reperfusion after cerebral ischemia.
Chi OZ; Barsoum S; Vega-Cotto NM; Jacinto E; Liu X; Mellender SJ; Weiss HR
Neuroscience; 2016 Mar; 316():321-7. PubMed ID: 26742793
[TBL] [Abstract][Full Text] [Related]
9. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
Jeong A; Wong M
Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
[TBL] [Abstract][Full Text] [Related]
10. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
11. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.
Rozas NS; Redell JB; McKenna J; Moore AN; Gambello MJ; Dash PK
Biochem Biophys Res Commun; 2015 Feb; 457(4):635-9. PubMed ID: 25613864
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
Ehninger D; Silva AJ
Trends Mol Med; 2011 Feb; 17(2):78-87. PubMed ID: 21115397
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.
Sato A; Kasai S; Kobayashi T; Takamatsu Y; Hino O; Ikeda K; Mizuguchi M
Nat Commun; 2012; 3():1292. PubMed ID: 23250422
[TBL] [Abstract][Full Text] [Related]
14. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
15. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
16. The mechanistic target of rapamycin (mTOR) pathway and S6 Kinase mediate diazoxide preconditioning in primary rat cortical neurons.
Dutta S; Rutkai I; Katakam PV; Busija DW
J Neurochem; 2015 Sep; 134(5):845-56. PubMed ID: 26016889
[TBL] [Abstract][Full Text] [Related]
17. Abnormal cortical cells and astrocytomas in the Eker rat model of tuberous sclerosis complex.
Takahashi DK; Dinday MT; Barbaro NM; Baraban SC
Epilepsia; 2004 Dec; 45(12):1525-30. PubMed ID: 15571510
[TBL] [Abstract][Full Text] [Related]
18. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
Davis PE; Peters JM; Krueger DA; Sahin M
Neurotherapeutics; 2015 Jul; 12(3):572-83. PubMed ID: 25986747
[TBL] [Abstract][Full Text] [Related]
19. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
Rensing N; Han L; Wong M
Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
[TBL] [Abstract][Full Text] [Related]
20. A brain proteomic investigation of rapamycin effects in the
Wesseling H; Elgersma Y; Bahn S
Mol Autism; 2017; 8():41. PubMed ID: 28775826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
